• Explore /
  • Poster
  • / Updated efficacy and safety results from the phase I study of intermittent dosing of the dual MEK/RAF inhibitor, RO5126766 in patients (pts) with <i>RAS/RAF</i> mutated advanced solid tumours.

Updated efficacy and safety results from the phase I study of intermittent dosing of the dual MEK/RAF inhibitor, RO5126766 in patients (pts) with RAS/RAF mutated advanced solid tumours.

Abstract Poster

Authors

null

Samuel John Harris

The Royal Marsden/Institute of Cancer Research, London, United Kingdom

Samuel John Harris , Maria Jose de Miguel Luken , Desamparados Roda Perez , Raquel Perez Lopez , Mona Parmar , Vasanthi Prathapan , Hasina Hassam , Alison Joanne Turner , Sonia Serrano Fandos , Emma Hall , Holly Tovey , Nina Tunariu , Juanita Suzanne Lopez , Timothy Anthony Yap , Johann S. De Bono , Udai Banerji

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT02407509

Citation

J Clin Oncol 34, 2016 (suppl; abstr 2582)

DOI

10.1200/JCO.2016.34.15_suppl.2582

Abstract #

2582

Poster Bd #

282

Abstract Disclosures

Similar Posters

First Author: Susana N. Banerjee

First Author: Marwan Fakih

First Author: S. R. Ahmed

First Author: Joshua E. Reuss